AGN Panoramica delle azioni Algernon Pharmaceuticals Inc. opera come società di sviluppo farmaceutico in fase clinica in Canada e Australia. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Algernon Pharmaceuticals Inc. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Algernon Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione CA$0.11 Massimo di 52 settimane CA$0.17 Minimo di 52 settimane CA$0.06 Beta -0.25 Variazione di 1 mese 46.67% Variazione a 3 mesi 29.41% Variazione di 1 anno 46.67% Variazione a 3 anni -93.43% Variazione a 5 anni -94.82% Variazione dall'IPO -99.53%
Notizie e aggiornamenti recenti
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent Jan 06
New major risk - Financial position Dec 24 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding Aug 20
New major risk - Shareholder dilution Aug 15 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Aug 08
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding Aug 02
Vedi altri aggiornamenti
Algernon Pharmaceuticals Receives Notice of Allowance from USPTO for Repirinast in Kidney Disease Patent Jan 06
New major risk - Financial position Dec 24 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.2352 million in funding Aug 20
New major risk - Shareholder dilution Aug 15 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Aug 08
Algernon Pharmaceuticals Inc. announced that it has received CAD 0.408 million in funding Aug 02
Algernon Pharmaceuticals Inc. Reports Results of Study Showing 93% Cough Suppression with Ifenprodil Jul 16 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.25 million in funding Jul 12
New major risk - Shareholder dilution Jun 09
New major risk - Shareholder dilution May 12
Algernon Pharmaceuticals Inc., Annual General Meeting, Jul 10, 2024 Apr 28 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding Apr 11
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset Apr 03
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis Jan 25 Algernon Pharmaceuticals Inc. announced that it has received CAD 0.28 million in funding Dec 28
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.15 million in funding Dec 13
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD Nov 30
New major risk - Share price stability Nov 24 Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 0.205 million in funding Jul 15
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase Feb 17
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board Jan 12
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Jan 10
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis Dec 06
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study Nov 17
Less than half of directors are independent Nov 16
Algernon Pharmaceuticals Inc. Enters into A Clinical Trial Agreement with Yale University for A DMT Phase 2 Depression Study Nov 09
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. Fda for Ifenprodil as A Treatment of IPF Sep 20
Algernon Pharmaceuticals Inc. Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study Sep 13
Algernon Pharmaceuticals Inc. Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Sep 02 Algernon Pharmaceuticals Inc. announced that it has received funding from AlphaNorth Asset Management Aug 28
Algernon Pharmaceuticals Inc. announced that it has received CAD 1.402125 million in funding Aug 24
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding Aug 20
Algernon Pharmaceuticals Inc. announced that it expects to receive CAD 1.402125 million in funding Aug 19
Algernon Pharmaceuticals Reports Additional Positive Data from Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Jul 29
Algernon Pharmaceuticals Hits Co-Primary Endpoint in Its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough Jul 19
Algernon Pharmaceuticals Inc. Provides Update on Its Planned Phase 1 Repirinast Chronic Kidney Disease Study Jul 12
Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study Jul 08 Algernon Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 1.159189 million. Jul 05
Algernon Pharmaceuticals Inc. Announces Patients Requested Ongoing Supply of Ifenprodil After IPF and Chronic Cough Phase 2 Study Ended Jun 22 Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough Jun 14
Algernon Pharmaceuticals Inc. Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough May 06
Less than half of directors are independent Apr 27
Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study Apr 27
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program Feb 24
Algernon Pharmaceuticals Announces Completion of Enrollment in Its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Feb 05
Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022 Jan 30
Algernon Pharmaceuticals Inc., Annual General Meeting, Feb 28, 2022 Jan 29
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of Its Psychedelic Drug Dmt Intellectual Property Jan 25
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study Jan 20
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study Jan 16
Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial Dec 03
Chief Financial Officer Michael S. Sadhra has left the company Dec 02
Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study Nov 25
Algernon Pharmaceuticals Inc. Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study Sep 24
Algernon Pharmaceuticals Inc. Plans to File Pre-Investigational New Drug Meeting Request with U.S. Food and Drug Administration for NP-120 (Ifenprodil) Phase 2 Chronic Cough Study Sep 21
Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program Aug 12
Algernon Pharmaceuticals Inc. Targets First Human Study of Its Psychedelic Drug DMT Stroke Program for fourth quarter of 2021 Jun 18
Algernon Pharmaceuticals Inc. Launches Pancreatic Cancer Clinical Research Program with Ifenprodil Jun 04
Algernon Pharmaceuticals Inc. Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke May 28
Algernon Pharmaceuticals Inc. Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke May 18
Algernon Pharmaceuticals Inc. Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study May 13
Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study May 12
Algernon Pharmaceuticals Inc. Files End of Phase 2 Meeting Request with U.S. FDA for Its Covid-19 Trial of Ifenprodil Apr 27
Algernon Pharmaceuticals Inc. Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke Mar 18
Algernon Pharmaceuticals Inc. Provides Update on Timing of Topline Results for Phase 2B/3 Covid-19 Trial of Ifenprodil Mar 13
Algernon Pharmaceuticals Inc. announced that it has received CAD 2.81501 million in funding Mar 07 Algernon Pharmaceuticals Announces Management Changes
Chief Science Officer has left the company Mar 02
Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data Feb 18
Algernon Pharmaceuticals Inc. Considers Adding Lung Scarring as an Additional Endpoint for Its Phase 2B/3 Covid-19 Study Protocol Feb 11
Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies Feb 10
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT The Spirit Molecule Feb 02
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for Covid-19 Jan 20
Algernon Pharmaceuticals Announces Clinical Research Plans for 2021 Jan 08
Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2B/3 Human Study of Ifenprodil for COVID-19 Dec 26
New 90-day low: CA$0.22 Dec 24
Algernon Pharmaceuticals Provides Additional Information on Phase 2B/3 Ifenprodil Covid-19 Study Interim Data Dec 19
Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study Dec 17
New 90-day high: CA$0.35 Dec 02
Algernon Pharmaceuticals Announces Enrollment of Final Patient in Its Multinational Phase 2B/3 Human Study of Ifenprodil for COVID-19 Dec 01 Rendimenti per gli azionisti AGN CA Pharmaceuticals CA Mercato 7D 37.5% 4.0% -0.9% 1Y 46.7% -47.0% 18.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: AGN ha superato il Canadian Pharmaceuticals che ha restituito -47 % nell'ultimo anno.
Rendimento vs Mercato: AGN ha superato il mercato Canadian che ha restituito 18.4 % nell'ultimo anno.
Volatilità dei prezzi Is AGN's price volatile compared to industry and market? AGN volatility AGN Average Weekly Movement 13.0% Pharmaceuticals Industry Average Movement 13.2% Market Average Movement 8.6% 10% most volatile stocks in CA Market 18.5% 10% least volatile stocks in CA Market 3.0%
Prezzo delle azioni stabile: AGN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Canadian.
Volatilità nel tempo: La volatilità settimanale ( 13% ) di AGN è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Algernon Pharmaceuticals Inc. opera come società di sviluppo farmaceutico in fase clinica in Canada e Australia. L'azienda si concentra sullo sviluppo di farmaci terapeutici nelle aree della steatoepatite non alcolica, delle malattie epatiche, delle malattie renali croniche e del programma ictus. La sua pipeline comprende Ifenprodil, in fase di sperimentazione clinica 2b per il trattamento della fibrosi polmonare idiopatica e della tosse cronica; repirinast, in fase di sperimentazione clinica 1 per il trattamento della malattia renale cronica; e N,N-Dimetiltriptamina, in fase di sperimentazione clinica 1 per il trattamento dell'ictus e delle lesioni cerebrali traumatiche.
Mostra di più Algernon Pharmaceuticals Inc. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Algernon Pharmaceuticals con la sua capitalizzazione di mercato? AGN statistiche fondamentali Capitalizzazione di mercato CA$2.02m Guadagni(TTM ) -CA$362.49k Ricavi(TTM ) n/a
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) AGN Conto economico (TTM ) Ricavi CA$0 Costo del fatturato CA$0 Profitto lordo CA$0 Altre spese CA$362.49k Guadagni -CA$362.49k
Ultimi guadagni dichiarati
Nov 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.017 Margine lordo 0.00% Margine di profitto netto 0.00% Rapporto debito/patrimonio netto 0%
Come si è comportato AGN nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/02/06 06:01 Prezzo dell'azione a fine giornata 2025/02/06 00:00 Guadagni 2024/11/30 Guadagni annuali 2024/08/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github .
Fonti analitiche Algernon Pharmaceuticals Inc. è coperta da 1 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Andre Uddin Research Capital Corporation
